Close Menu

Genetics & Genomics Business, Policy & Funding

Breaking news on Genetics & Genomics business, policy & funding.

In Q2 the firm filed for FDA Emergency Use Authorization for its saliva-based Advanta Sx SARS-CoV-2 RT-PCR assay as it continued its pivot to COVID-19 testing.

NantHealth's net loss more than tripled in the second quarter, though it continues to build up its cash reserves.

The Bay Area DNA synthesis company said it was "not significantly affected" by the COVID-19 pandemic and beat Wall Street revenue estimates.

Although its research test volume decreased significantly because of the COVID-19 pandemic, the company saw revenue growth across both clinical testing and development services.

The San Diego genomic analysis firm said the decline in revenues was due to the COVID-19 pandemic.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.